IDEXX Laboratories, Inc. has announced impressive third quarter results for 2026, showcasing a 10% increase in revenue and raising its revenue guidance for the year. This performance highlights the company's strong position in the In Vitro & In Vivo Diagnostic Substances industry, driven by innovation and effective commercial execution.

On November 2, 2026, IDEXX Laboratories (Nasdaq: IDXX) reported revenues of $1,214 million for the third quarter, marking a 10% growth as reported and organic. The Companion Animal Group (CAG) also demonstrated robust growth, contributing to the overall revenue increase. The company’s earnings per diluted share (EPS) reached $4.01, an 18% increase compared to the previous year.

Background

IDEXX Laboratories, Inc., headquartered in Westbrook, Maine, is a leading provider of diagnostic solutions for pet healthcare. The company operates within the In Vitro & In Vivo Diagnostic Substances sector (SIC: 2835) and is recognized for its innovative products and services that enhance veterinary practices. IDEXX is listed on the Nasdaq under the ticker IDXX.

What the Filing Says

The filing details that IDEXX achieved a 10% growth in revenue for the third quarter of 2026, with organic and recurring revenue from CAG diagnostics growing by 11%. The company placed over 1,900 IDEXX inVue Dx analyzers during the quarter, increasing its installed base to nearly 11,000 instruments. The EPS of $4.01 reflects an 18% increase, with operating margins improving by 100 basis points.

Impact

This strong performance may affect various stakeholders, including investors, customers, and competitors. Investors are likely to view the results positively, as the raised revenue guidance indicates continued growth potential. Customers may benefit from IDEXX's ongoing innovations, while competitors may find it challenging to keep pace with IDEXX's growth and market presence.

What's Next

The filing does not specify what happens next, but the raised guidance suggests that IDEXX will continue to focus on its growth strategy and innovation in the diagnostic substances sector.